Early data from a clinical study suggest that blocking the Bruton tyrosine kinase (BTK) protein with the cancer drug acalabrutinib provided clinical benefit to a small group of patients with severe COVID-19.
from Health & Medicine News -- ScienceDaily https://www.sciencedaily.com/releases/2020/06/200605140516.htm
No comments:
Post a Comment